Cooperative Agreement U01CA294459
Award Date
9/1/24
Completion Date
8/31/29
Dollars Obligated
$1M
Federal Agency
National Cancer Institute
Federal Grant Program
93.353
Assistance Type
Cooperative Agreement
Place of Performance
Houston, TX 77030, USA
Similar Awards
This $1,069,188 Cooperative Agreement award, provided by the National Cancer Institute (NCI) under the 21st Century Cures Act - Beau Biden Cancer Moonshot program (CFDA 93.353), supports a collaborative research project to construct a comparative spatial atlas of low-grade gliomas. The research team from the University of California, Los Angeles (UCLA) Neurosurgery and the California Institute of Technology (Caltech) Spatial Single Cell team will expand on their preliminary data to generate an...
This Cooperative Agreement award, with a total funding of $1,069,873, was granted by the National Cancer Institute under the 21st Century Cures Act - Beau Biden Cancer Moonshot program (CFDA 93.353). The award aims to establish the Center for Gastric Pre-Cancer Atlas of Multidimensional Evolution in 3D (GAME3D) to develop a multimodal, single-cell, dynamic, and 3D spatial atlas of normal-appearing gastric mucosa, early precancerous lesions, and advanced gastric cancer in individuals with...
This Cooperative Agreement, awarded by the National Cancer Institute (NCI) under the 21st Century Cures Act - Beau Biden Cancer Moonshot federal grant program (CFDA 93.353), will fund the construction of a three-dimensional (3D) multimodal molecular atlas of colorectal cancer (CRC) across different ages of onset. The $1,063,411 award to Vanderbilt University will support spatial mapping of tumor progression from precancerous to cancerous states, utilizing cutting-edge technologies such as...
The National Cancer Institute (NCI) awarded a $1,019,013 Cooperative Agreement under the 21st Century Cures Act - Beau Biden Cancer Moonshot program (CFDA 93.353) to the Regents of the University of California, San Francisco (UCSF) to develop a Pre-Cancer Atlas of Skin Cancer. The overarching goal is to study the early stages of skin cancer development, including melanoma and cutaneous squamous cell carcinoma, and the role of the immune system in this transition from pre-cancer to cancer. The...
This federal Cooperative Agreement award, funded by the National Cancer Institute under the 21st Century Cures Act - Beau Biden Cancer Moonshot program (CFDA 93.353), aims to create a comprehensive 3D atlas depicting the progression of pancreatic cancer precursor lesions to invasive pancreatic ductal adenocarcinoma (PDAC) in individuals with genetic defects in DNA repair genes (BRCA1, BRCA2, PALB2). The $1,035,138 award, with a period of performance from Sep 1, 2024 to Aug 31, 2029, will support...
This Cooperative Agreement award from the National Cancer Institute (NCI) under the 21st Century Cures Act - Beau Biden Cancer Moonshot program (CFDA 93.353) will fund the establishment of the Human Prostate Tumor Atlas Center (HPTAC) at Washington University in St. Louis. The $1,032,520 award, effective September 1, 2024 through August 31, 2029, will support the development of a molecularly resolved spatial atlas of prostate cancer (PCa). The atlas will integrate multi-omics, imaging, and...
This $1,018,682 Cooperative Agreement award from the National Cancer Institute (NCI) under the 21st Century Cures Act - Beau Biden Cancer Moonshot program (CFDA 93.353) aims to construct a spatiotemporal atlas of human follicular lymphoma (FL) transformation to diffuse large B-cell lymphoma (DLBCL) and angioimmunoblastic T-cell lymphoma (AITL) evolution. The award to Yale University will leverage single-cell and spatial omics technologies to map the major cell types, mutational landscapes,...
This $1,149,870 Cooperative Agreement award from the National Cancer Institute (NCI) under the 21st Century Cures Act - Beau Biden Cancer Moonshot program (CFDA 93.353) will establish a Pediatric Solid Tumor Microenvironment (PSTME) Atlas. The primary goal is to investigate the unique tumor microenvironments of prominent pediatric cancers like rhabdomyosarcoma, neuroblastoma, and Wilms tumors, with the aim of uncovering mechanisms of therapy resistance and identifying vulnerabilities for more...
This $1,128,990 Cooperative Agreement award from the National Cancer Institute (CFDA 93.353 - 21st Century Cures Act - Beau Biden Cancer Moonshot) will fund the Myeloma Multidimensional Precancer Atlas (MMPCA) project at the Dana-Farber Cancer Institute. The project aims to construct a comprehensive spatial and temporal atlas of precursor stages of multiple myeloma (MM) to understand genomic and microenvironmental alterations across the disease spectrum. Key objectives include: Mapping spatial...
The University of Texas MD Anderson Cancer Center received a $647,995 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to conduct research on image-guided bidirectional EphB4 agonist-based therapy for ovarian cancer. The award period runs from September 1, 2023 to August 31, 2027. As a leading cancer treatment and research institution, MD Anderson has extensive experience delivering a wide range of cancer-related...